bioAffinity Regains Compliance With Nasdaq Listing Requirements

The company received confirmation from Nasdaq that it has regained compliance with the minimum bid price and rights and warrants rules, canceling the previously scheduled hearing. Maintaining its stock listing is critical for the biotech firm to focus on the commercialization of its CyPath Lung test and shareholder value.